Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD17002 in Mild to Moderate COVID-19
NCT05069610Phase 2Completed
- Sponsor
- Advagene Biopharma Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD-17002 in coronavirus disease 2019 (COVID-19), sponsored by Advagene Biopharma Co., Ltd.. Started Mar 2022; status: completed.
02
Drugs
AD-17002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05069610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069610.